InvestorsHub Logo
Followers 62
Posts 7582
Boards Moderated 1
Alias Born 01/02/2003

Re: Whalatane post# 389797

Sunday, 10/02/2022 8:46:02 AM

Sunday, October 02, 2022 8:46:02 AM

Post# of 427306
KIWI...This is an interesting proposition...

QUOTE..."The rebates are to the large healthcare providers like Kaiser ….It’s a volume discount with a commitment purchase"....i.e. We ( Kaiser ) will purchase ( as example ) 100,000 bottles of Vascepa (1 mth supply per bottle ) for 2022 as long as it’s at least 1 c lower per bottle then the cost of the generic option"

Could this be the basis of a deal with China, which has a very large population, which could benefit from Vascepa?....i.e. We will give a very cheap price in return for enormous volume...As J.T. was wont to say...Vascepa is a volume play...not a price play.

Also. if China agreed on such deal, Amarin could then lower its prices for Vascepa in Europe and the U.S.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News